Skip to main content
SpringerLink
Log in

Limaprost

  • Adis Drug Profile
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

  • ▴ Limaprost, an alprostadil (prostaglandin E1) analogue, is a vasodilator that increases blood flow and inhibits platelet aggregation.

  • ▴ The efficacy of oral limaprost was evaluated in adult Japanese patients in three randomised, double-blind, 6-week trials. One study included patients with thromboangiitis obliterans and two trials included patients with lumbar spinal canal stenosis. Limaprost was generally well tolerated and serious adverse events were uncommon.

  • ▴ Thromboangiitis Obliterans: In a randomised, double-blind trial in Japanese patients primarily with thromboangiitis obliterans (n = 136), there was no significant difference between patients receiving limaprost 30 μg/day and those receiving oral ticlopidine 500 μg/day in the improvement of ischaemic symptoms.

  • ▴ Lumbar Spinal Canal Stenosis: Limaprost 15 μg/ day was superior to limaprost 3 μg/day for overall drug usefulness and overall improvement from baseline to study end in a phase III trial in 146 patients with lumbar spinal canal stenosis. Assessment of overall improvement considered various objective symptoms (e.g. muscle strength, walking ability) and subjective symptoms (e.g. pain or numbness in extremities), while overall usefulness also considered safety issues.

  • ▴ The efficacy of limaprost 15 μg/day was not significantly different from that of 30 μg/day, but tended to be better than that of 6 μg/day in a phase II trial in patients with lumbar spinal canal stenosis and normal straight leg raise test results. The optimal dosage of limaprost for this indication was therefore deemed to be 15 μg/day.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Ono Pharmaceutical Co Ltd. Additional indication approved for limaprost, oral prostaglandin E1 derivative (media release) [online]. Available from URL: http://www.ono.co.jp [Accessed 2006 Apr 12]

  2. Szuba A, Cooke JP. Thromboangiitis obliterans: an update on Buerger’s disease. West J Med 1998 Apr; 168 (4): 255–60

    PubMed  CAS  Google Scholar 

  3. Olin JW. Thromboangiitis obliterans (Buerger’s disease). N Engl J Med 2000 Sep 21; 343 (12): 864–9

    Article  PubMed  CAS  Google Scholar 

  4. Sweetman SC. Martindale: the complete drug reference. 34th ed. London: Pharmaceutical Press, 2005

    Google Scholar 

  5. Arbit E, Pannullo S. Lumbar stenosis: a clinical review. Clin Orthop Relat Res 2001 Mar; (384): 137–43

  6. Alvarez JA, Hardy Jr RH. Lumbar spine stenosis: a common cause of back and leg pain. Am Fam Physician 1998 Apr 15; 57 (8): 1825–39

    PubMed  CAS  Google Scholar 

  7. Chosa E, Sekimoto T, Kubo S, et al. Evaluation of circulatory compromise in the leg in lumbar spinal canal stenosis. Clin Orthop Relat Res 2005 Feb; (431): 129–33

  8. Snyder DL, Doggett D, Turkelson C. Treatment of degenerative lumbar spinal stenosis. Am Fam Physician 2004 Aug 1; 70 (3): 517–20

    PubMed  Google Scholar 

  9. Ono Pharmaceutical Co Ltd. Opalmon® tablets 5 μg prescribing information [online]. Available from URL: http://www.esearch.ne.jp/~jpr/PDF/ONO06.PDF [Accessed 2006 Apr 21]

  10. Kitagawa T, Wakitani K, Ogaki Y, et al. Effects of a prostaglandin E1 analogue, OP-1206·α-cyclodextrin clathrate (OP-1206·α-CD) in a model of experimental peripheral circulation disorder in rats [in Japanese]. Gendai Iryo 1986; 18 Suppl. II: 1–11

    Google Scholar 

  11. Tsuboi T, Hatano K, Nakatsuji B, et al. Pharmacological evaluation of OP 1206, a prostaglandin E1 derivative, as an antianginal agent. Arch Int Pharmacodyn Ther 1980; 247 (1): 89–102

    PubMed  CAS  Google Scholar 

  12. Kitagawa T, Sakaguchi N, Kira H, et al. Effects of a prostaglandin E1 analogue, OP-1206·α-cyclodextrin clathrate (OP-1206·α-CD) on the femoral arterial blood flow, hindlimb cutaneous blood flow and hindlimb cutaneous temperature [in Japanese]. Gendai Iryo 1986; 18 Suppl. II: 12–20

    Google Scholar 

  13. Tsuboi T, Fujitani B, Maeda J, et al. Effect of OP 1206, a prostaglandin E1 derivative, on guinea-pig platelet functions. Thromb Res 1980; 20 (5–6): 573–80

    Article  PubMed  CAS  Google Scholar 

  14. Fujitani B, Watanabe M, Kuwashima J, et al. Effect of a prostaglandin E1 derivative (OP-1206) and acetylsalicyclic acid on electrically induced thrombosis in guinea-pig mesenteric artery and its modification by an inhibitor of prostaglandin 12 synthetase, tranylcypromine. Jap J Pharmacol 1986; 40: 31–5

    Article  PubMed  CAS  Google Scholar 

  15. Maeda Y, Kanayama S, Okajima Y, et al. Effect of PGE1 analogue (ONO-1206) on the platelet functions [in Japanese]. Ketsueki to Myakkan 1982; 13 (1): 142–5

    Google Scholar 

  16. Yamamoto T, Hiromoto J. Phase I clinical trial of 17(S)-methyl-omega-homo-trans-delta2-prostaglandinE1·α-cyclodextrin (OP-1206·α-CD): part 1. Single dose study [in Japanese]. Yakuri To Chiryo 1981; 9 (4): 1463–76

    Google Scholar 

  17. Ito K, Nagashima K, Takenobu Y, et al. Effect of OP-1206 · α-CD on cauda equina blood flow in dog cauda equina with experimental compression [in Japanese]. Kiso to Rinsho 1995; 29 (10): 2577–85

    Google Scholar 

  18. Sawaragi H, Takenobu Y, Nonaka S, et al. Effect of OP-1206 α CD on the thermal hyperalgesia induced by constriction injury to the sciatic nerve in the rat [in Japanese]. Kiso to Rinsho 1996; 30 (2): 237–44

    Google Scholar 

  19. Takenobu Y, Katsube N, Nakai H. Effect of OP-1206· α-CD on the walking dysfunction in the rat cauda equina nerve compressed model [in Japanese]. Kiso to Rinsho 1996; 30 (2): 221–7

    Google Scholar 

  20. Sekiguchi M, Kikuchi S, Konno S. Effects of liimaprost, an orally-active prostaglandin E1 analogue, in a model of experimental acute cauda equine compression: a study using a video recording system (digital hi-scope) [in Japanese]. Progr ad Med 2002; 22 (2): 443–5

    Google Scholar 

  21. Kayama S, Konno S, Kikuchi S, et al. Effect of OP-1206 α-CD (prostaglandin E1 derivative) on nerve conduction velocity in the dog cauda equina subjected to acute experimental compression [in Japanese]. Kiso to Rinsho 1996; 30 (2): 229–36

    Google Scholar 

  22. Fujitani B, Kii Y, Tashibu H, et al. Effect of OP-1206 · α-CD on electromyograms in sciatic nerve-ligated rate [in Japanese]. Kiso to Rinsho 1996; 30 (2): 245–50

    Google Scholar 

  23. Liu Y, Noguchi K, Takenobu Y, et al. Comparison the effect of beraprost sodium with that of limaprost alfadex in rat neuropathic intermittent claudication model [in Japanese]. Jpn Pharmacol Ther 2002; 30 (10): 875–80

    CAS  Google Scholar 

  24. Mikami H, Hishita N, Itoh T. Clinical pharmacokinetic study of a single oral administration of limaprost alfadex (Prorenal®) [in Japanese]. Rinsho Iyaku 2005; 21 (3): 361–6

    Google Scholar 

  25. Komaba J, Masuda Y, Nako S, et al. Clinical pharmacokinetic study of Opalmon® (limaprost alfadex) tablet in healthy Japanese male volunteers [in Japanese]. Igaku to Yakugaku 2005; 53 (2): 265–71

    CAS  Google Scholar 

  26. Miyamoto S, Taniguchi K, Kajiwara I, et al. Pharmacokinetics of OP-1206·α-cyclodextrin clathrate (OP-1206·α-CD): first report: absorption and excretion after oral and intracaudal administration in rats [in Japanese]. Gendai Iryo 1986; 18 Suppl. II: 56–69

    CAS  Google Scholar 

  27. Miyamoto S, Kida J, Okada K, et al. Pharmacokinetics of OP-1206-cyclodextrin clathrate (OP-1206-CD): second report: distribution after oral administration in rats [in Japanese]. Gendai Iryo 1986; 18 Suppl. II: 70–9

    Google Scholar 

  28. Miyamoto S, Ishido M, Sawada M, et al. Pharmacokinetics of OP-1206·α-cyclodextrin clathrate (OP-1206·α-CD): third report: metabolism in rats [in Japanese]. Gendai Iryo 1986; 18 Suppl. II: 80–103

    Google Scholar 

  29. Kusaba A, Tanabe T, Mishima Y, et al. Therapeutic effect of OP-1206·α-CD in patients with chronic arterial occlusive disease of the extremities: double-blind comparative trial with ticlopidine [in Japanese]. J Clin Exp Med 1986; 138: 217–26

    Google Scholar 

  30. Kurihara A, Kataoka O, Sugawara S, et al. Clinical benefit of OP-1206·α-CD on lumbar spinal canal stenosis: multi-center comparative double-blind clinical study [in Japanese]. Rinsho Iyaku 1996; 12 (3): 511–29

    Google Scholar 

  31. Uratsuji M, Kurihara A, Iguchi T, et al. The optimal dose for OP-1206 · α-CD on lumbar spinal canal stenosis: multi-center comparative double-blind clinical study [in Japanese]. Rinsho Iyaku 1996; 12 (3): 489–509

    Google Scholar 

  32. Ono Pharmaceutical Co Ltd. Postmarketing surveillance: April 2001–March 2004: Prospective Central Registration System Trial [data on file]. Japan: Ono Pharmaceutical Co, Ltd, 2006

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Wolters Kluwer Health / Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland, 1311, New Zealand

    Tracy Swainston Harrison & Greg L. Plosker

  2. Wolters Kluwer Health, Conshohocken, Pennsylvania, USA

    Tracy Swainston Harrison & Greg L. Plosker

Authors
  1. Tracy Swainston Harrison
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Greg L. Plosker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tracy Swainston Harrison.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Harrison, T.S., Plosker, G.L. Limaprost. Drugs 67, 109–118 (2007). https://doi.org/10.2165/00003495-200767010-00010

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200767010-00010

Keywords

Search

Navigation